Skip to content

Plethysmographic Pulse-contour and Pulse-wave-transit-times for Haemodynamic Evaluation in Bleeding Simulation

Plethysmographic Pulse-contour and Pulse-wave-transit-times for Haemodynamic Evaluation in Bleeding Simulation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03481855
Acronym
Plethysmo
Enrollment
30
Registered
2018-03-29
Start date
2018-03-06
Completion date
2018-04-11
Last updated
2018-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health, Subjective

Brief summary

The evaluation of haemodynamic changes is still challenging in clinically relevant situations (e.g. in bleeding, septic and postoperative patients) with the conventional monitoring routinely used including heart rate and mean arterial pressure. If the arterial pressure drops and the heart increases, the haemodynamic state is already decompensated and a therapy is at risk being indicated too late. Prior to decompensation - still in the state of compensated shock - it would be desirable to detect the shock already. The compensated shock is characterized by an occult drop of cardiac output and a hypoperfusion of vital organs like e.g. the splanchnic region. Due to these pathophysiological characteristics, a therapy would be indicated already in this stadium of shock progression. The available monitoring tools to detect compensated shock are on the one hand side invasive (intravascular catheter), cost-intensive (cost of the catheter systems), or need extensive training (echocardiography). Consequently, the implementation of advanced haemodynamic monitoring is still low despite the high clinical relevance for the patients. It is the goal of this project to evaluate in healthy volunteers the routinely implemented technology of photo-plethysmography in its ability to detect haemodynamic changes by extended signal analysis of the pulse-contour and the pulse-wave-transit-times in relation to the gold-standard echocardiography. Secondary goal of this study is to analyse the physiological and haemodynamic changes during progressive central hypovolaemia displayed by non-invasive or minimal-invasive monitoring devices and associate the changes to each other.

Interventions

DEVICELower-body-low-pressure chamber

The lower-body-low-pressure chamber administers a negative pressure to the lower part of the body (below the waist) to induce a central hypovolaemia by pooling of blood in the legs according to Tymko, M. FACETS, Bd. 1, Nr. 1, S. 225-244, März 2017 and Esch, B.T.A. et al. AJP Adv. Physiol. Educ., Bd. 31, Nr. 1, S. 76-81, März 2007.

Sponsors

Technische Universität Berlin
CollaboratorOTHER
Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to 40 Years

Inclusion criteria

* Offered patient information and written informed consent * Existence of valid health insurance * Male gender

Exclusion criteria

* Patients aged less than 18 years or more than 40 years * Inability of German language use * Lacking willingness to save and hand out data within the study * Evidence of a chronic disease (cardio-vascular, renal, pulmonary, neurological, metabolic, gastro-intestinal) * Chronic medication * Signs of a reduced cardiorespiratory capacity * Signs of an acute illness * Participation in a prospective intervention trial during the study period * Anamnestic hints for syncope or disposition to hypotension * Signs of arterial hypertension * Signs of inguinal hernia * Relevant pathologies in the baseline examination of the transthoracic echocardiography * For the bio-impedance measurements: heart defibrillator

Design outcomes

Primary

MeasureTime frameDescription
Changes in the pulse-contour-analysis of the plethysmographic signalTime course of 40 minutes (at study baseline, at study intervention level 1, 2 and 3 and recovery time)The pulse-contour of the plethysmographic signal will be analyzed to detect morphological changes over time in relation to the initial baseline recording
Changes the pulse-wave-transit-times of the plethysmographic signalTime course of 40 minutes (at study baseline, at study intervention level 1, 2 and 3 and recovery time)The pulse-wave-transit-times of the plethysmographic signal will be analyzed to detect changes over time in relation to the initial baseline recording

Secondary

MeasureTime frameDescription
Echocardiographic parameter to determine the cardiac performance of the left ventricleAt baseline (up to minute 7 after starting the study protocol), during the study intervention level 1, 2 and 3 (between minute 8 up to minute 28 after starting study protocol) and recovery after finishing the study intervention (between minute 30 and 40)The performance of the left ventricle will be analyzed by a transthoracic echocardiography by a physician certified by the European Society of Cardiology
Echocardiographic parameter to determine the cardiac performance of the left atriumAt baseline (up to minute 7 after starting the study protocol), during the study intervention level 1, 2 and 3 (between minute 8 up to minute 28 after starting study protocol) and recovery after finishing the study intervention (between minute 30 and 40)The performance of the left atrium will be analyzed by a transthoracic echocardiography by a physician certified by the European Society of Cardiology
Echocardiographic parameter to determine the cardiac performance of the right ventricleAt baseline (up to minute 7 after starting the study protocol), during the study intervention level 1, 2 and 3 (between minute 8 up to minute 28 after starting study protocol) and recovery after finishing the study intervention (between minute 30 and 40)The performance of the right ventricle will be analyzed by a transthoracic echocardiography by a physician certified by the European Society of Cardiology
Echocardiographic parameter to determine the cardiac performance of the right atriumAt baseline (up to minute 7 after starting the study protocol), during the study intervention level 1, 2 and 3 (between minute 8 up to minute 28 after starting study protocol) and recovery after finishing the study intervention (between minute 30 and 40)The performance of the right atrium will be analyzed by a transthoracic echocardiography by a physician certified by the European Society of Cardiology
Echocardiographic parameter to analyze the vena cava inferiorAt baseline (up to minute 7 after starting the study protocol), during the study intervention level 1, 2 and 3 (between minute 8 up to minute 28 after starting study protocol) and recovery after finishing the study intervention (between minute 30 and 40)The analysis will be assessed by a subcostal approach by transthoracic echocardiography
Heart rate variabilityAt baseline (up to minute 7 after starting the study protocol), during the study intervention level 1, 2 and 3 (between minute 8 up to minute 28 after starting study protocol) and recovery after finishing the study intervention (between minute 30 and 40)Heart rate variability calculated from raw biosignals Bioelectrical signals by standardized analysis algorithms
Haemodynamic parameter of the bio-impedance monitoringTime course of 40 minutes (at study baseline, at study intervention level 1, 2 and 3 and recovery time)The parameter will be determined by the electrical cardiometry/bio-impedance monitoring device of Osypka Medical
Arterial blood pressureAt baseline (up to minute 7 after starting the study protocol), during the study intervention level 1, 2 and 3 (between minute 8 up to minute 28 after starting study protocol) and recovery after finishing the study intervention (between minute 30 and 40)Arterial blood pressure determined by non-invasive monitoring
Heart soundsTime course of 40 minutes (at study baseline, at study intervention level 1, 2 and 3 and recovery time)Heart sounds measured by vibration sensors
Tonometric arterial blood pressureTime course of 40 minutes (at study baseline, at study intervention level 1, 2 and 3 and recovery time)Tonometric arterial blood pressure measured by applanation tonometer
Haemodynamic parameter of the tonometric pulse-contour methodTime course of 40 minutes (at study baseline, at study intervention level 1, 2 and 3 and recovery time)The parameter will be determined by the non-invasive monitoring device Finapress
Mean systemic filling pressureAt baseline (up to minute 7 after starting the study protocol), during the study intervention level 1, 2 and 3 (between minute 8 up to minute 28 after starting study protocol) and recovery after finishing the study intervention (between minute 30 and 40)The parameters describing the characteristics of the venous return determined by the stop-flow method
Questionnaire regarding alimentationImmediately prior to the start of the study protocolThe questionnaire directs to characterize the intake of fluid and solid alimentation prior to the study protocol
Bio-impedance analysis of the body fluidImmediately prior to the start of the study protocolThe bio-impedance analysis of the body fluid directs to determine the water content of the body
Shock indices of the bio-impedance monitoringTime course of 40 minutes (at study baseline, at study intervention level 1, 2 and 3 and recovery time)The parameter will be determined by the electrical cardiometry/bio-impedance monitoring device of Osypka Medical
Heart rateAt baseline (up to minute 7 after starting the study protocol), during the study intervention level 1, 2 and 3 (between minute 8 up to minute 28 after starting study protocol) and recovery after finishing the study intervention (between minute 30 and 40)Heart rate determined by non-invasive monitoring

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026